These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 3337297)

  • 21. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV?
    Schatzberg AF; Rothschild AJ
    Am J Psychiatry; 1992 Jun; 149(6):733-45. PubMed ID: 1590491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical effects of abrupt withdrawal from tri-cyclic antidepressants and monoamine oxidase inhibitors after long-term treatment.
    Tyrer P
    J Affect Disord; 1984 Feb; 6(1):1-7. PubMed ID: 6231324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discontinuation study.
    Robinson DS; Lerfald SC; Bennett B; Laux D; Devereaux E; Kayser A; Corcella J; Albright D
    Psychopharmacol Bull; 1991; 27(1):31-9. PubMed ID: 1862204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenelzine treatment of depression with chronic diarrhea.
    Weiss KJ; Schwartz HJ; Berrettini WH
    J Clin Psychiatry; 1982 Jun; 43(6):250-1. PubMed ID: 7085581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Atypical depression: evolution toward a specific pharmacologic and efficacious treatment?].
    Dassylva B; Fontaine R
    Can J Psychiatry; 1995 Mar; 40(2):102-8. PubMed ID: 7788612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tricyclic nonresponders: phenomenology and treatment.
    Roose SP; Glassman AH; Walsh BT; Woodring S
    Am J Psychiatry; 1986 Mar; 143(3):345-8. PubMed ID: 3953869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can mildly depressed outpatients with atypical depression benefit from antidepressants?
    Stewart JW; McGrath PJ; Quitkin FM
    Am J Psychiatry; 1992 May; 149(5):615-9. PubMed ID: 1575250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treating DSM-IV depression with atypical features.
    Stewart JW; Thase ME
    J Clin Psychiatry; 2007 Apr; 68(4):e10. PubMed ID: 17474800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comments on article by Dr Birkenhager et al: "Efficacy of imipramine in psychotic versus nonpsychotic depression".
    Baldessarini RJ
    J Clin Psychopharmacol; 2008 Dec; 28(6):716; author reply 717-8. PubMed ID: 19011451
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients.
    Birkenhäger TK; van den Broek WW; Mulder PG; Bruijn JA; Moleman P
    J Clin Psychiatry; 2004 Nov; 65(11):1505-10. PubMed ID: 15554763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of imipramine in psychotic versus nonpsychotic depression.
    Birkenhager TK; van den Broek WW; Mulder PG; Moleman P; Bruijn JA
    J Clin Psychopharmacol; 2008 Apr; 28(2):166-70. PubMed ID: 18344726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychotic vs. nonpsychotic depression: comparison of treatment response.
    Brown RP; Frances A; Kocsis JH; Mann JJ
    J Nerv Ment Dis; 1982 Oct; 170(10):635-7. PubMed ID: 6125562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to phenelzine among depressed patients with features of hysteroid dysphoria.
    Kayser A; Robinson DS; Nies A; Howard D
    Am J Psychiatry; 1985 Apr; 142(4):486-8. PubMed ID: 3883817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement.
    Celada P; Pérez J; Alvarez E; Artigas F
    J Clin Psychopharmacol; 1992 Oct; 12(5):309-15. PubMed ID: 1282522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An open study of triiodothyronine augmentation of tricyclic antidepressants in inpatients with refractory depression.
    Birkenhäger TK; Vegt M; Nolen WA
    Pharmacopsychiatry; 1997 Jan; 30(1):23-6. PubMed ID: 9065966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of platelet monoamine oxidase in depressed subjects treated with phenelzine.
    Davidson J; McLeod MN; White HL
    Am J Psychiatry; 1978 Apr; 135(4):470-2. PubMed ID: 345826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.
    Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
    Clin Neuropharmacol; 1993; 16 Suppl 2():S51-4. PubMed ID: 8313397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triiodothyronine potentiation of the antidepressant effect of phenelzine.
    Joffe RT
    J Clin Psychiatry; 1988 Oct; 49(10):409-10. PubMed ID: 3170493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression.
    König F; Wolfersdorf M
    Pharmacopsychiatry; 1997 May; 30(3):93-6. PubMed ID: 9211570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression.
    Rothschild AJ; Samson JA; Bessette MP; Carter-Campbell JT
    J Clin Psychiatry; 1993 Sep; 54(9):338-42. PubMed ID: 8104930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.